Protagonist Therapeutics (NASDAQ:PTGX): A High Growth Momentum Stock Meeting the Mark Minervini Technical Setup
Protagonist Therapeutics Inc PTGX
$136.64
▼ -1.44%
($-2.00)
📅 Earnings This Week
Open
$138.36
Prev Close
$138.64
Day Range
$131.69 – $138.37
52W Range
$50.49 – $143.29
Market Cap
$8.79B
Beta
1.78
EPS (TTM)
$-1.80
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2016-08-11 |
| Shares Out. | 64,310,000 |
| Website | protagonist-inc.com/ ↗ |
| Phone | 13026365401 |
| Employees | 131 |
| Revenue | $56.4M |
| Gross Profit | $56.4M |
| Net Income | $3.8M |
| Free Cash Flow | -$117.9M |
| Total Assets | $697.5M |
| Total Liabilities | $42.0M |
| Equity | $655.5M |
About Protagonist Therapeutics Inc
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
Protagonist Therapeutics Inc is a publicly traded company under the ticker symbol PTGX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
20 analysts (2026-07-01)